Abstract

ObjectiveStudies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus.
Cristiana Sieiro Santos ... Carolina Álvarez Castro
Musculoskeletal care | VOL. 20
Cristiana Sieiro Santos, et. al.Cristiana Sieiro Santos ... Carolina Álvarez Castro
26 May 2022
PO.8.180 Biomarkers before conception related to adverse pregnancy outcomes in patients with systemic lupus erythematosus and primary sjögren’s syndrome: a retrospective cohort study
Gm Verstappen ... H Bootsma
Lupus Science & Medicine | VOL. 9
Gm Verstappen, et. al.Gm Verstappen ... H Bootsma
27 Sep 2022
24 The role of complement and complement inhibition in APS pregnancy
Jane Salmon
-
Jane SalmonJane Salmon
28 Mar 2021
Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren’s syndrome: a retrospective cohort study
Hendrika Bootsma ... Karina De Leeuw
RMD Open | VOL. 9
Hendrika Bootsma, et. al.Hendrika Bootsma ... Karina De Leeuw
01 Aug 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers